deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT03662711

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease

Comparison of 1-year Treatment With Inhaled Long Acting Bronchodilators (LABD) Plus Inhaled Glucocorticosteroids (ICS) Versus LABD Without ICS on Re-hospitalizations and/or Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (COPD) Recently Hospitalized Because of an Acute Exacerbation of COPD (ICS-Life Study).

Sponsor: Università degli Studi di Ferrara

Conditions Pulmonary Disease, Chronic Obstructive
Interventions Bronchodilator Agents
Updated 14 times since 2018 Last updated: Dec 23, 2022 Started: Nov 11, 2018 Primary completion: Oct 26, 2022 Completion: Oct 26, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Contract terminated between AIFA and the Sponsor (University of Ferrara)

Other Pulmonary Disease, Chronic Obstructive trials with similar outcome

Browse all Pulmonary Disease, Chronic Obstructive trials

Listed as NCT03662711, this PHASE4 trial focuses on Pulmonary Disease, Chronic Obstructive and remains terminated or withdrawn. Sponsored by Università degli Studi di Ferrara, it has been updated 14 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~May 2019 · 4 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Jul 2020 · 8 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Dec 2022 · 13 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  4. Feb 2023 — Jul 2024 [monthly]

    Terminated PHASE4

  5. Jan 2023 — Feb 2023 [monthly]

    Terminated PHASE4

▶ Show 9 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE4

    Status: Recruiting → Terminated

  2. Nov 2021 — Dec 2022 [monthly]

    Recruiting PHASE4

  3. Jan 2021 — Nov 2021 [monthly]

    Recruiting PHASE4

  4. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

  5. Nov 2019 — Jul 2020 [monthly]

    Recruiting PHASE4

  6. Jul 2019 — Nov 2019 [monthly]

    Recruiting PHASE4

  7. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE4

  8. Jan 2019 — May 2019 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  9. Oct 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Università degli Studi di Ferrara
Data source: Università degli Studi di Ferrara

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bari, Italy , Battipaglia, Italy , Bergamo, Italy , Cassano delle Murge, Italy , Catania, Italy , Catanzaro, Italy , Chieri, Italy , Cremona, Italy , Crotone, Italy , Ferrara, Italy and 25 more locations